Actinium Pharmaceuticals (ATNM)

• Market cap: $47.1M
• 1 day: 4.14%
• 5 days: 4.14%
• 1 month: 16.15%
• 3 months: -7.36%
• 6 months: -5.03%
• Year to date: 19.84%
• 1 year: 20.8%
• 5 years: -87.14%
• 10 years: -97.06%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Employees: 31